|
|
|
|
|
|
By Tyler Menichiello, contributing editor | I spoke to Iovance Biotherapeutics to learn about the company's preparation leading up to the approval of Amtagvi, the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy aimed at treating solid tumors. |
|
|
|
|
Expert panelists address why apheresis material for autologous cell therapy is subject to variability related to its limited quantity, patient differences, and variations across apheresis facilities. |
|
|
|
| A Robust Alternative To Plasmid DNA For AAV Production | Poster | By A. Navarro, S. Maestro, A. Etxabe, et al., Viralgen | Review a comparison of side-by-side plasmids and neDNA for AAV production in the Pro10 cell line, using different AAV capsid serotypes and productions scales. |
|
|
|
| The Future Of Plasmid DNA Upstream Optimization | Article | AGC Biologics | Understand why an optimized upstream manufacturing process is vital for meeting the increasing demand for plasmid DNA in various therapeutic and vaccine applications. |
|
|
|
| Accelerating Treg Therapy Manufacturing | Case Study | ElevateBio | Learn about the strategies that helped accelerate the development timeline and build a process to isolate, engineer, and expand mature, thymic Tregs. |
|
|
|
|
|
| Genome editing holds immense promise for treating genetic diseases, but off-target effects remain a significant concern. To ensure the safety and efficacy of genome editing therapies, researchers are developing various strategies to reduce off-target effects. Register today for the next Cell & Gene Live. Attendance is free thanks to the support of Bio-Techne. |
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
